See Spot’s Drugmaker Snag A Quarterly Sales Beat

Animal health giant Zoetis (ZTS) beat fourth-quarter sales expectations Tuesday and issued a strong 2023 outlook, leading ZTS stock to pop.

X

During the December period, sales rose 4% to $2.04 billion, narrowly topping forecasts for $2 billion, according to FactSet. Adjusted earnings jumped 15% to $1.15 per share and met estimates. The best growth came from the pet division, where sales rose 10%. Sales of medications for livestock toppled 7%.

For the year, Zoetis called for $8.575 billion to $8.725 billion in sales. The low end of the guidance came in above ZTS stock analysts’ call for $8.56 billion. The company also expects adjusted income of $5.34-$5.44 per share. Analysts projected $5.40 per share, a penny above the midpoint of Zoetis’ outlook.

In premarket action on the stock market today, ZTS stock advanced 2.8% near 167.80.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Teva Plots Its Knockoff Of Axsome’s New Depression Drug, Sending The Biotech Sprawling

The Cream Of The Crop: 5 Biotech Stocks That Outrank 98% Of All Stocks

Options Trading: How To Start Using Options, How To Manage Risk

See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks